<DOC>
	<DOCNO>NCT01641172</DOCNO>
	<brief_summary>Taste smell abnormality common cancer patient undergo chemotherapy , prevalence range 46 % 77 % taste change , 35 % 75 % smell change . These chemosensory change distress patient lead change appetite , food choice , nutrient intake . These change result malnutrition weight loss . Possibly , also unhealthy eat pattern develop due taste smell change , give high prevalence obesity among survivor certain cancer type . The primary objective investigate nature , prevalence , duration taste smell change patient disseminate testicular cancer treat cisplatin base chemotherapy .</brief_summary>
	<brief_title>Taste , Smell Chemotherapy ( TASTY )</brief_title>
	<detailed_description>Rationale : Taste smell abnormality common cancer patient undergo chemotherapy , prevalence range 46 % 77 % taste change , 35 % 75 % smell change . These chemosensory change distress patient lead change appetite , food choice , nutrient intake . These change result malnutrition weight loss . Possibly , also unhealthy eat pattern develop due taste smell change , give high prevalence obesity among survivor certain cancer type . Objective : The primary objective investigate nature , prevalence , duration taste smell change patient disseminate testicular cancer treat cisplatin base chemotherapy . Secondary objective explore short- long-term consequence chemosensory change ( medical ) food preference , dietary intake quality life , investigate appreciation medical food product testicular cancer patient . Furthermore , assess whether change taste smell relate metabolic syndrome , whether chemotherapy induce neurotoxicity relate change taste smell . Study design : The present study longitudinal ( measurement first chemotherapy , day 7 first course , second course , day 7 second course , 1 month start last course , 7 month start chemotherapy , 1 year start chemotherapy ) cross-sectional ( measurement 1 , 3 , 5 7 year chemotherapy ) design . Patients start participation study start chemotherapy , result longitudinal data patient start participation year treatment , result cross-sectional data . Study population : Patients disseminate testicular cancer treat cisplatin base chemotherapy . This group select , young age diagnosis , emetogenic chemotherapy treatment , high survival rate , increase body mass index ( BMI ) risk cardiovascular disease long-term . Intervention : Gustatory function test use filter-paper taste strip measure recognition threshold sweet , salty , sour bitter taste . Olfactory function test use Sniffin ' Sticks measure odor threshold , discrimination recognition . Besides , patient fill questionnaires assess taste smell subjectively assess QoL . Food preference investigate show standardized photographs sweet savory food product , vary fat protein content . In addition , set 10 Oral Nutrition Supplements ( ONS ) offer combined questionnaire measure appreciation preference food product . All test questionnaire perform longitudinally ( first chemotherapy , day 7 first course , second course , day 7 second course , 1 month start last course , 7 month start chemotherapy , 1 year start chemotherapy ) cross-sectional ( 1 , 3 , 5 7 year chemotherapy ) . Two day food record use investigate actual dietary intake first second course , ( day 5 6 ) first second course , 1 month start last course , 7 month start chemotherapy , 1 year start chemotherapy . A Food Frequency Questionnaire ( FFQ ) use investigate usual dietary intake start first course , second course , 1 month start last course , seven month start chemotherapy , 1 year start chemotherapy ( longitudinal ) , 1 , 3 , 5 7 year chemotherapy ( cross-sectional ) . A Dual Energy X-ray Absortiometrys ( DEXA ) scan use get insight possible change bone fat mass chemotherapy . To detect possible cause taste smell change , audiogram perform ( measure cisplatin induced neurotoxicity ) , baroreflex sensitivity ( BRS ) ( measure quality shortterm blood pressure maintenance ) , blood glucose tolerance , insulin resistance , DNA SNP analysis collect . The DEXA scan , audiogram , BRS test , blood glucose tolerance test perform first course chemotherapy , one month start last course , 1 year start chemotherapy ( longitudinal part ) , 1 , 3 , 5 7 year chemotherapy ( cross-sectional part ) . A blood sample DNA analysis take start chemotherapy ( longitudinal part ) , 1 , 3 , 5 7 year chemotherapy ( cross-sectional part ) .</detailed_description>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<criteria>Patients disseminate testicular cancer undergo first line cisplatin base chemotherapy ( BEP EP ) . Age 1850 year start treatment . Signed informed consent . Ability comprehend Dutch ( read write ) . Complete remission cisplatin base chemotherapy ( BEP EP ) without adjunctive surgery active followup ( crosssectional part study ) . Mental disability Patients comorbidities affect gustatory olfactory function , rhinosinusitis , liver renal problem , hyperactivity hypoactivity thyroid gland , diabetes , neurologic disorder ( crosssectional part study ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>taste</keyword>
	<keyword>smell</keyword>
	<keyword>cancer</keyword>
	<keyword>nutrition</keyword>
</DOC>